Brief: Helix Biopharma and Moffitt Cancer Center to investigate L-DOS47 and checkpoint blockade
18/07/2017 22:02
July 18 (Reuters) - Helix Biopharma Corp HBP.TO
* Helix Biopharma Corp and Moffitt Cancer Center to
investigate L-DOS47 and checkpoint blockade
* Helix Biopharma -L-DOS47 therapy provides alternative
pharmacologic approach to neutralizing tumor acidity that may
improve response of immune checkpoint inhibitors
Source text for Eikon: ID:nCCNFj2vSa
Further company coverage: HBP.TO
((bangalore.newsroom@thomsonreuters.com;))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020